Skip to main content

Zai Lab

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States focused on bringing transformative medicines for oncology, autoimmune disorders, infectious diseases, and neurological disorders to patients in China and around the world. Zai Lab is a fully integrated biopharmaceutical company with end-to-end capabilities. Zai has internal R&D centers to advance its discovery pipeline, a strong clinical development team that currently manages more than 50 ongoing or planned clinical trials, small-molecule and large-molecule manufacturing facilities, an experienced regulatory affairs group, and a highly specialized commercial team to support marketing of innovative products. Our goal is to leverage our competencies and resources to positively impact human health worldwide.